High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma.

ABSTRACT:

Background

MiT-Renal Cell Carcinoma (RCC) is characterized by genomic translocations involving microphthalmia-associated transcription factor (MiT) family members TFE3, TFEB, or MITF. MiT-RCC represents a specific subtype of sporadic RCC that is predominantly seen in young patients and can present with heterogeneous histological features making diagnosis challenging. Moreover, the disease biology of this aggressive cancer is poorly understood and there is no accepted standard of care therapy for patients with advanced disease. Tumor-derived cell lines have been established from human TFE3-RCC providing useful models for preclinical studies.

Methods

TFE3-RCC tumor derived cell lines and their tissues of origin were characterized by IHC and gene expression analyses. An unbiase

SUBMITTER: Lang M 

PROVIDER: S-EPMC10127337 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature